RETINA Roundup

AAO 2026 – Clinical Trial Updates Part II

Jovany Franco, MD
Kellogg Eye Center, University of Michigan, Ann Harbor, MI

Subretinal Gene Therapy Laru-zova for X-linked Retinitis Pigmentosa (XLRP): Pivotal VISTA Trial First-time Results
Robert Sisk, MD

The session began with Dr. Sisk, who presented 12 month results from VISTA, a phase 3 trial evaluating the subretinal gene therapy laruparetigene zovaparvovec (laru-zova) for RPGR-associated X-linked retinitis pigmentosa. The study enrolled 85 male participants aged 12 to 50 years with best-corrected visual acuity (BCVA) of 20/30 to 20/200, a detectable ellipsoid zone on OCT, and sufficient fixation and sensitivity on microperimetry. Those enrolled were randomized to one of two doses of laru-zova or the untreated control group. Both treatment doses met the primary endpoint, demonstrating significant improvements in low-luminance visual acuity compared with control. Approximately half of treated patients gained at least two lines of low-luminance visual acuity, with microperimetry outcomes also favoring the treatment cohorts. Adverse events (AEs) were generally mild to moderate, though two serious surgical AEs, comprised of a macular hole and rhegmatogenous retinal detachment, were reported in the lower-dose cohort.

During discussion, Dr. Sisk shared that initial screening challenges were creatively mitigated through use of a mobile vision van equipped to perform OCT and microperimetry to pre-screen potential participants. He also noted that baseline ellipsoid zone status and retinal sensitivity appeared more important than age in predicting treatment response. When asked about data that seemed to suggest an apparent decline in microperimetry sensitivity following initial improvement, Dr. Sisk proposed that some photoreceptors may be inevitably destined to degenerate despite exhibiting an initial treatment response.

Topline 24-Month Results from the Phase 3 DRAGON Study of Tinlarebant for Adolescent Stargardt Disease
Quan Dong Nguyen, MD

The session continued with Dr. Nguyen, who presented 24 month results from DRAGON, a phase 3 trial evaluating tinlarebant, a retinol-binding protein 4 (RBP4) antagonist for ABCA4-associated Stargardt disease. The trial included 104 participants aged 12 to 20 years with BCVA 20/200 or better and definitely decreased autofluorescence (DDAF) lesion size of 3 disc areas or less. Participants were randomized 2:1 to daily oral tinlarebant 5 mg or placebo. The study met its primary endpoint, with a 36% reduction in DDAF lesion growth in the tinlarebant group when compared with placebo. A secondary endpoint combining DDAF and questionably decreased autofluorescence (QDAF) showed a 34% reduction. Visual acuity remained largely unchanged in both groups. Treatment was generally well tolerated; six serious AEs were reported, though all events were felt to be unrelated or unlikely related to the study drug.

During discussion, the panel posed questions regarding the clinical relevance of DDAF lesion growth as a trial endpoint. In response, Dr. Nguyen highlighted a structure-function analysis performed within DRAGON involving nearly 3,000 microperimetry stimulus locations, which demonstrated differences in retinal sensitivity across autofluorescence-defined regions, including DDAF, QDAF, and transitional areas. Discussion then transitioned to reported disturbances in dark adaptation associated with the drug and their potential impact on treatment adherence; here, Dr. Nguyen shared that these symptoms were generally mild and transient.

ROP 4 Study
G. Baker Hubbard, MD

Dr. Hubbard then took the podium, sharing 12 month results from ROP4, a randomized trial comparing lower-dose (0.063 mg) and standard-dose (0.25 mg) bevacizumab for severe zone 1 retinopathy of prematurity (ROP) in 77 infants. The study defined treatment success as improvement in neovascularization (NV) within four days of treatment along with no recurrence or need for additional treatment for severe NV within four weeks. Treatment success was observed in all infants in the lower-dose group and approximately 95% of those in the standard-dose group. Through 12 months, more eyes receiving lower-dose bevacizumab required additional treatment for reactivation; in contrast, a greater proportion of eyes in the standard-dose group required prophylactic treatment for persistent peripheral avascular retina. Refractive and ocular alignment outcomes were similar at 12 months, with no instances of retinal detachment or macular ectopia across groups.

During discussion, Dr. Hubbard acknowledged lack of retinal imaging as a limitation of the study and cited variable imaging infrastructure at participating centers as a significant barrier. He also highlighted practical challenges associated with lower bevacizumab dosing, including the need for dilution and possible underdosing due to air bubbles at the time of administration. The importance of longer-term follow-up was also discussed; here, Dr. Hubbard shared that the planned two-year outcome measures for ROP4, including neurodevelopmental assessments, may help better inform whether lower-dose bevacizumab offers meaningful advantages over standard dosing.

Vamikibart for Uveitic Macular Edema: Week 52 Efficacy and Safety Results From the Phase 3 MEERKAT and SANDCAT Trials
Nisha Acharya, MD

Dr. Acharya then presented 52 week results from MEERKAT (245 participants) and SANDCAT (256 participants). These two identically designed phase 3 trials evaluated intravitreally-administered vamikibart, an anti-IL-6 monoclonal antibody, for uveitic macular edema. Patients received four monthly injections of vamikibart 0.25 mg, 1 mg, or sham. The primary endpoint was a gain of at least 15 ETDRS letters at 16 weeks. While both doses met the primary endpoint in MEERKAT, the 1 mg group did not achieve statistical significance in SANDCAT, and thus results for the 0.25 mg comparison were considered nominally significant. When examining trends in BCVA and central subfield thickness (CST), rapid improvement with subsequent sustained effects were observed through 16 and 52 weeks in the treatment arms (except for a narrowing in treatment response in the 1 mg group at 52 weeks in SANDCAT). Approximately 20% of vamikibart-treated patients required rescue therapy versus more than 50% of sham-treated patients. Among patients eligible for PRN treatment after 20 weeks, approximately 30% required additional injections with 85% of these patients requiring only one. The therapy was generally well tolerated, with few serious ocular AEs reported, including no cases of occlusive retinal vasculitis.

During discussion, Dr. Acharya opined that heterogeneity amongst uveitis patients makes a 15-letter visual acuity gain a challenging endpoint. More specifically, she suggested that differences in the underlying cause of inflammation as well as the presence of other drivers of visual impairment in uveitic eyes may have contributed to the discordant trial findings.

 

Exit mobile version